title: Miltefosine: a novel treatment option for mast cell-mediated diseases.
abstract: Mast cell-mediated diseases such as urticaria, mastocytosis and atopic dermatitis are common, disabling and hard to treat. Recently, the lipid raft modulator miltefosine has been shown to inhibit mast cell activation in vitro and in vivo. Moreover, three randomized and placebo-controlled trials have assessed the effects of miltefosine in mast cell-driven conditions. Here, we review the experimental and clinical evidence in support of miltefosine as a novel treatment option for mast cell-mediated diseases and we discuss the most imminent questions and issues that need to be addressed by future research and clinical trials.
authors.affiliation: Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany. marcus.maurer@charite.de
authors.forename: Marcus
authors.initials: M
authors.lastname: Maurer
authors.forename: Markus
authors.initials: M
authors.lastname: Magerl
authors.forename: Martin
authors.initials: M
authors.lastname: Metz
authors.forename: Karsten
authors.initials: K
authors.lastname: Weller
authors.forename: Frank
authors.initials: F
authors.lastname: Siebenhaar
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000188:drug therapy; D006801:Humans; D008407:Mast Cells / Q000187:drug effects; D008415:Mastocytosis / Q000188:drug therapy / Q000628:therapy; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014582:Urticaria Pigmentosa / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D010767:Phosphorylcholine; C039128:miltefosine